Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642365 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT04642365 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 49 participants.
The verdict
NCT04642365, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.
Interventions
- DRUG Atezolizumab
- DRUG RO7296682
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2024-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04642365
The ClinicalTrials.gov registry entry for NCT04642365 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04642365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04642365 about?
NCT04642365 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.". This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.
What is the current status of trial NCT04642365?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2021-01-04. Estimated completion is 2024-01-04.
What interventions are being tested in trial NCT04642365?
The interventions under investigation include: Atezolizumab (DRUG), RO7296682 (DRUG).
Who is sponsoring clinical trial NCT04642365?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.